The trend of managing prostate cancer in Taiwan

International Journal of Urology

Volumn 11, Issue 7, 2004, Pages 510-514

  Wong, Ai Yan ^a   Chen, Shyh Chyan ^b   Chueh, Shih Chieh ^b   Chen, Jun ^b  

^a Ten Chan General Hospital   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Practice pattern; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CLINICAL PRACTICE; DIAGNOSTIC TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; QUESTIONNAIRE; TAIWAN;

HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; QUESTIONNAIRES; TAIWAN; UROLOGY;

EID: 4043133114     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00836.x     Document Type: Article

References (17)

1. Fleshner N, Rakovitch E, Klotz L. Differences between urologists in the United States and Canada in the approach to prostate cancer. J. Urol. 2000; 163: 1461-6.
2. Ramsey EW, Elhilali M, Gidenberg SL et al. Practice pattern of Canadian urologists in benign prostatic hyperplasia and prostate cancer. J. Urol. 2000; 163: 499-502.
3. Oesterling JE, Martin SK, Bergstralh EJ et al. The use of prostatic specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60.
4. Peters SM, Jovell AJ, Garcia-Altes A, Serra-Prat M. Screening and clinical management of prostate cancer. A cross-national comparison. Int. J. Tech. Assess. 2001; 17: 215-21.
5. Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostatic specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-12.
6. Haukaas S, Roervik J, Halvorsen OJ et al. When is bone scintigraphy necessary in the assessment of the newly diagnosed untreated prostate cancer? Br. J. Urol. 1997; 79: 770-76.
7. Kindrick AV, Grossfield GD, Stier DM et al. Use imaging test for staging newly diagnosed prostate cancer: trends from the CaPSURE database. J. Urol. 1998; 160: 2102-106.
8. Coopeberg MR, Lubeck DP, Grossfield GD et al. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J. Urol. 2002; 168: 491-5.
9. Saigal CS, Pashos CL, Henning JM, Litwin MS. Variations in use of imaging in a national sample of men with early-stage prostate cancer. Urology 2002; 59: 400-404.
10. Wong WY, Chen SC, Chueh SC, Chen J. Trends for managing benign prostatic hyperplasia in Taiwan. J. Urol. ROC 2002; 13: 25-31.
11. McConnell JD, Barry MJ, Bruskewitz RC et al. Clinical practice guidelines. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Benign Prostatic Hyperplasia Guideline Panel. Agency for Health Care Policy and Research, Rockville, MD, 1994.
12. Koyanagi T, Artibani W, Correa R et al. Initial diagnostic evaluation of men with lower urinary tract symptoms. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia. Paris, France, 1997.
13. Prostate Cancer Trialists' Collaborative Group. Maximal androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-9.
14. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 1998; 339: 1036-42.
15. Patterson SG, Balducci L, Pow-Sang JM. Controversies surrounding androgen deprivation for prostate cancer. Cancer Cont. 2002; 9: 315-25.
16. Rambeaud JJ. Intermittent complete androgen blockade in metastatic prostate cancer. Eur. Urol. 1999; 35: 32-6.
17. Naylor CD, Guyatt GH. Users' guide to the medical literature. XI. How to use an article about a clinical utilization review. Evidence-Based Medicine Working Group. JAMA 1996; 273: 1435-9.